
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
Here are the key points to know about the National Comprehensive Cancer Network’s guidelines on treating cancer during the COVID-19 pandemic.
The National Comprehensive Cancer Network (NCCN) recently published guidelines on the care of patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic. Here is a snapshot of what they recommend on:
For the latest updates on COVID-19 and cancer — and all things oncology nursing — subscribe to





